Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Johnson and Johnson
Boehringer Ingelheim
Merck
Express Scripts

Last Updated: September 26, 2022

Details for Patent: 9,649,456


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 9,649,456
Title:Nasal administration
Abstract: A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece (47) for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit (16) which is operable to deliver the powdered substance through the nosepiece (47).
Inventor(s): Djupesland; Per Gisle (Oslo, NO), Hafner; Roderick Peter (Swindon, GB)
Assignee: OptiNose AS (Oslo, NO)
Application Number:12/594,365
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Device; Dosage form;

Drugs Protected by US Patent 9,649,456

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y ACUTE TREATMENT OF MIGRAINE See Plans and Pricing
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY See Plans and Pricing
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,649,456

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0706744.0Apr 5, 2007
PCT Information
PCT FiledApril 07, 2008PCT Application Number:PCT/GB2008/001226
PCT Publication Date:October 16, 2008PCT Publication Number: WO2008/122795

International Family Members for US Patent 9,649,456

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
United Kingdom 0706744 See Plans and Pricing
United Kingdom 2448183 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2008122795 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
AstraZeneca
Boehringer Ingelheim
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.